Safety · July 10, 2026
By Peppies · July 10, 2026 · 3 min read
Independent testing keeps finding the same thing: the contents often don't match the label.
The uncomfortable truth about the peptide grey market isn't a moral one - it's that no one is checking what's in the vial.
Peer-reviewed testing of falsified peptide products found purity ranging from 5% to 75%, with arsenic and lead above the limits set for injectable drugs. [1] A 2026 patient-safety white paper from ECRI and the Institute for Safe Medication Practices - naming BPC-157 and TB-500 among others - reached similar conclusions about contamination and dosing risk. [2]
Enforcement hasn't kept pace. Of 14 retatrutide vendors that had received FDA warning letters, eight were still actively selling months later, according to a CBS News investigation - enforcement "stalled at the warning-letter stage." [3]
This is why we keep drawing a hard line between a licensed compounding pharmacy - state-board regulated, USP standards, prescription required - and an anonymous "research use only" seller shipping unidentified powder. They are not the same thing, and conflating them tars the accountable channel with the sins of the black market.
If you've had a bad reaction to any product, the single most useful thing you can do is report it to the FDA's MedWatch program. It's free, and the agency's own scientists rely on that data.
